Sangamo Therapeutics has patented a method for inactivating the human glucocorticoid receptor gene to retain immune function during glucocorticoid treatment. The method involves introducing zinc finger nucleases and a transgene into isolated human cells. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sangamo Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Gene inactivation for immune function retention during glucocorticoid treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Sangamo Therapeutics Inc

A recently granted patent (Publication Number: US11884930B2) discloses a method for selecting isolated human cells with a transgene integrated into an endogenous glucocorticoid receptor (GR) gene. The method involves introducing specific polynucleotides encoding zinc finger nucleases (ZFN) and a transgene flanked by homology arms targeting the human GR gene into the cells. The integration of the transgene into the GR gene is facilitated by the action of the ZFN, which have a zinc finger DNA-binding domain with specific recognition helices.

Furthermore, the patent claims specify that the corticosteroid used in the method is synthetic, with dexamethasone being a specific example. The introduction of the necessary components into the isolated human cells can be achieved through the use of a viral vector, with options including replication-defective adenovirus, hybrid adenovirus, or non-integrating lentivirus. The detailed description of the method and the specific components involved provide a novel approach to selecting human cells with integrated transgenes, particularly within the context of the glucocorticoid receptor gene.

To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies